Listed

Resmed Inc: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on Apr 28, 2023 and accepted by EDGAR at Apr 27, 2023, 19:15 ET.

Share

Management's discussion and analysis

As filed, 1,338 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Purchases of equity securities. On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program.

We temporarily suspended our share repurchase program due to recent acquisitions and as a response to the COVID-19 pandemic. As a result, we did not repurchase any shares during the three months ended March 31, 2023. However, there is no expiration date for this program, and we may, at any time, elect to resume the share repurchase program as the circumstances allow. Since the inception of the share buyback programs, we have repurchased 41.8 million shares at a total cost of $1.6 billion. At March 31, 2023, 12.9 million additional shares of common stock can be repurchased under the approved share repurchase program.

Controls and procedures

As filed, 2,376 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2023.

On November 21, 2022, we completed the acquisition of MEDIFOX DAN. Under guidelines established by the SEC, companies are permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. Based on those guidelines, our assessment of the effectiveness of our internal control over financial reporting will exclude MEDIFOX DAN. We are in the process of integrating MEDIFOX DAN into our system of internal control over financial reporting.

Except as noted above, there has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 390 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The discussion of our business and operations should be read together with the risk factors and contained in our annual report on Form 10-K for the fiscal year ended June 30, 2022, which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. As of March 31, 2023, there have been no further material changes to such risk factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$1.12bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-07-01 to 2023-03-31$3.10bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-01-01 to 2023-03-31$499.1mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2022-07-01 to 2023-03-31$1.36bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-01-01 to 2023-03-31$617.8mus-gaap:GrossProfit
Gross profit9 months2022-07-01 to 2023-03-31$1.74bnus-gaap:GrossProfit
Research and development3 months2023-01-01 to 2023-03-31$76.4mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-07-01 to 2023-03-31$209.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-01-01 to 2023-03-31$228.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2022-07-01 to 2023-03-31$633.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-01-01 to 2023-03-31$300.7mus-gaap:OperatingIncomeLoss
Operating income9 months2022-07-01 to 2023-03-31$856.6mus-gaap:OperatingIncomeLoss
Income tax3 months2023-01-01 to 2023-03-31$56.9mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-07-01 to 2023-03-31$157.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-01-01 to 2023-03-31$232.5mus-gaap:NetIncomeLoss
Net income9 months2022-07-01 to 2023-03-31$667.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-01-01 to 2023-03-31$1.58us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-07-01 to 2023-03-31$4.53us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-01-01 to 2023-03-31$1.58us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-07-01 to 2023-03-31$4.55us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-01-01 to 2023-03-31147,395,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-07-01 to 2023-03-31147,400,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-07-01 to 2023-03-31$455.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-07-01 to 2023-03-31$85.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2022-07-01 to 2023-03-31$193.6mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2023-03-31$227.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-03-31$2.34bnus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$6.71bnus-gaap:Assets
Current liabilitiesAt period end2023-03-31$761.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-03-31$2.78bnus-gaap:Liabilities
Long-term debtAt period end2023-03-31$1.58bnus-gaap:LongTermDebt
Short-term borrowingsAt period end2023-03-31$9.9mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2023-03-31$3.93bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000943819-23-000008. Last ingested by Listed: Nov 14, 2026, 17:21 ET. Listed shows no prices and gives no investment advice.